Drug Profile
Research programme: idiopathic pulmonary fibrosis therapeutic - MAbImprove/Sanofi
Alternative Names: Antibody therapeutic inhaled spray - MAbImprove/SanofiLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator MAbImprove; Sanofi
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in France (Inhalation, Spray)
- 24 Jan 2014 Early research in Idiopathic pulmonary fibrosis in France (Inhalation)